Last C$11.30 CAD
Change Today +0.05 / 0.44%
Volume 10.9K
RX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:59 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Open
C$11.30
Previous Close
C$11.25
Day High
C$11.60
Day Low
C$11.30
52 Week High
09/19/14 - C$12.82
52 Week Low
10/24/13 - C$2.66
Market Cap
156.0M
Average Volume 10 Days
62.8K
EPS TTM
C$0.21
Shares Outstanding
13.8M
EX-Date
--
P/E TM
53.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, engages in the marketing of pharmaceutical products in Canada. It is also involved in manufacturing and marketing non-chemical bio and health-friendly insecticides worldwide. The company markets FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; and FeraMAX Powder, an oral iron supplement. It also offers Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, and rectoscopies; and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, BioSyent Inc. manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$200.7K
Chief Financial Officer and Vice President
Total Annual Compensation: C$126.6K
Vice President of Biosyent Pharma Inc.
Total Annual Compensation: C$120.8K
Compensation as of Fiscal Year 2013.

biosyent inc (RX) Key Developments

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

BioSyent Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s total sales were $3,632,128, were 56% higher compared to $2,328,064 in the prior year period. Net income before tax was $1,350,645, which is 67% higher than $808,749 in third quarter of 2013. Net income after tax increased by 64% from $609,749 in third quarter of 2013 to $1,000,654 in third quarter of 2014. Basic & diluted earnings per share was $0.07 against $0.04 a year ago. For the nine months, the company’s total sales were $9,152,624 were 62% higher than the prior year period. Net income before tax was $3,258,172 or 78% higher than the corresponding prior year period. Net income after tax was $2,400,880 or 75% higher than the corresponding prior year period. Diluted EPS was $0.17 against $0.09 in corresponding prior year period.

BioSyent Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Plans to Launch a New Gastrointestinal Product in the Fourth Quarter of 2014

BioSyent Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues were CAD 3,072,395 compared to CAD 1,786,685 for the same period a year ago. Profit before tax was CAD 1,219,855 compared to CAD 542,964 for the same period a year ago. Profit after tax was CAD 888,805 compared to CAD 418,325 for the same period a year ago. Basic & diluted earnings per share was CAD 0.06 compared to CAD 0.03 for the same period a year ago. For the six months, the company reported revenues were CAD 5,520,496 compared to CAD 3,328,528 for the same period a year ago. Profit before tax was CAD 1,907,527 compared to CAD 1,024,927 for the same period a year ago. Profit after tax was CAD 1,400,226 compared to CAD 762,735 for the same period a year ago. Diluted earnings per share was CAD 0.10 compared to CAD 0.05 for the same period a year ago. The company plans to launch a new Gastrointestinal product in the fourth quarter of 2014. The company also received Health Canada approval on one of its two urgent care products and is planning to launch the product in late 2014 or early 2015.

BioSyent Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM

BioSyent Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$11.30 CAD +0.05

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies
 

Industry Analysis

RX

Industry Average

Valuation RX Industry Range
Price/Earnings 52.4x
Price/Sales 14.2x
Price/Book 21.7x
Price/Cash Flow 52.3x
TEV/Sales 13.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit www.biosyent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.